Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting - A randomized, controlled trial

被引:145
作者
Grinspoon, S
Corcoran, C
Parlman, K
Costello, M
Rosenthal, D
Anderson, E
Stanley, T
Schoenfeld, D
Burrows, B
Hayden, D
Basgoz, N
Klibanski, A
机构
[1] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Boston Univ, Sch Med, Boston, MA 02118 USA
[4] Boston Vet Adm Med Ctr, Boston, MA USA
关键词
D O I
10.7326/0003-4819-133-5-200009050-00010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Substantial loss of muscle mass occurs among men with AIDS wasting. Objective: To investigate the independent effects of testosterone therapy and progressive resistance training in eugonadal men with AIDS wasting. Design: Randomized, controlled trial. Setting: University hospital. Patients: 54 eugonadal men with AIDS wasting (weight < 90% ideal body weight or weight loss > 10%). Intervention: In a 2 x 2 factorial design, patients were assigned to receive testosterone enanthate (200 mg/wk) or placebo injections and progressive resistance training (three times weekly) or no training for 12 weeks. Measurements: Cross-sectional muscle area and other indices of muscle mass. Results: Cross-sectional muscle area increased in response to training compared with nontraining (change in arm muscle mass, 499 +/- 349 mm(2) vs. 206 +/- 264 mm(2) [P = 0.004]; change in leg muscle mass, 1106 +/- 854 mm(2) vs. 523 +/- 872 mm(2) [P = 0.045]) and in response to testosterone therapy compared with placebo (change in arm muscle mass, 512 +/- 371 mm(2) vs. 194 +/- 215 mm(2) [P < 0.001]; change in leg muscle mass, 1236 +/- 881 mm(2) vs. 399 +/- 729 mm(2) [P = 0.002]). Levels of high-density lipoprotein cholesterol decreased in response to testosterone therapy compared with placebo (-0.03 +/- 0.13 mmol/L vs. 0.05 +/- 0.13 mmol/L [-1 +/- 5 mg/dL vs. 2 +/- 5 mg/dL]; P = 0.011) and increased in response to training compared with nontraining (0.05 +/- 0.13 mmol/L vs. 0.00 +/- 0.16 mmol/L [2 +/- 5 mg/dL vs. 0 +/- 6 mg/dL]; P = 0.052). Conclusions: In contrast to anabolic therapies that may have adverse effects on metabolic variables, supervised exercise effectively increases muscle mass and is associated with significant positive health benefits in eugonadal men with AIDS wasting.
引用
收藏
页码:348 / 355
页数:8
相关论文
共 20 条
[1]  
*AM COL SPORTS MED, 1980, GUID GRAD EX TEST EX
[2]   QUANTITATIVE MOTOR-ASSESSMENT IN AMYOTROPHIC-LATERAL-SCLEROSIS [J].
ANDRES, PL ;
HEDLUND, W ;
FINISON, L ;
CONLON, T ;
FELMUS, M ;
MUNSAT, TL .
NEUROLOGY, 1986, 36 (07) :937-941
[3]   Effects of testosterone replacement with a nongenital, transdermal system, androderm, in human immunodeficiency virus-infected men with low testosterone levels [J].
Bhasin, S ;
Storer, TW ;
Asbel-Sethi, N ;
Kilbourne, A ;
Hays, R ;
Sinha-Hikim, I ;
Shen, RQ ;
Arver, S ;
Beall, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (09) :3155-3162
[4]   Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels [J].
Bhasin, S ;
Storer, TW ;
Javanbakht, M ;
Berman, N ;
Yarasheski, KE ;
Phillips, J ;
Dike, M ;
Sinha-Hikim, I ;
Shen, RQ ;
Hays, RD ;
Beall, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (06) :763-770
[5]   Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[6]  
Finison LJ, 1996, ARCH PHYS MED REHAB, V77, P1251
[7]  
FISHER A, 1998, 12 WORLD AIDS C GEN, P844
[8]  
GIBERT CL, 1998, 12 WORLD AIDS C GEN, P554
[9]   Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection [J].
Gold, J ;
High, HA ;
Li, YM ;
Michelmore, H ;
Bodsworth, NJ ;
Finlayson, R ;
Furner, VL ;
Allen, BJ ;
Oliver, CJ .
AIDS, 1996, 10 (07) :745-752
[10]   Quantitative assessment of cross-sectional muscle area, functional status, and muscle strength in men with the acquired immunodeficiency syndrome wasting syndrome [J].
Grinspoon, S ;
Corcoran, C ;
Rosenthal, D ;
Stanley, T ;
Parlman, K ;
Costello, M ;
Treat, M ;
Davis, S ;
Burrows, B ;
Basgoz, N ;
Klibanski, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (01) :201-206